證券時(shi)報(bao)e公(gong)司(si)訊，海南(nan)(nan)海藥(yao)(000566)9月3日晚間(jian)公(gong)告(gao)，控(kong)股子公(gong)司(si)海口市制(zhi)(zhi)藥(yao)廠與中南(nan)(nan)大(da)學聯合(he)申請的(de)氟非尼(ni)酮(tong)(tong)膠囊于近日收到I期臨(lin)(lin)床(chuang)試驗總(zong)結報(bao)告(gao)。氟非尼(ni)酮(tong)(tong)是一種(zhong)具有抗纖(xian)維(wei)(wei)化作(zuo)用的(de)吡啶酮(tong)(tong)類(lei)化合(he)物。臨(lin)(lin)床(chuang)前研究表(biao)明氟非尼(ni)酮(tong)(tong)能通(tong)過抗纖(xian)維(wei)(wei)化機制(zhi)(zhi)有效抑制(zhi)(zhi)肝纖(xian)維(wei)(wei)化的(de)發展(zhan)，臨(lin)(lin)床(chuang)I期結果(guo)表(biao)明氟非尼(ni)酮(tong)(tong)安全性和耐受(shou)性較好，目前國內外針對該靶點抗肝纖(xian)維(wei)(wei)化無(wu)上市的(de)藥(yao)品。Ⅱ期臨(lin)(lin)床(chuang)試驗工(gong)作(zuo)將于近期啟動。